Sam Brusco, Associate Editor05.08.24
Biosense Webster, a Johnson & Johnson MedTech company, launched its Carto 3 system Version 8, the latest version of its 3D heart mapping system for cardiac ablation procedures.
The new version of Carto 3 includes Cartsound Fam, an artificial intelligence (AI) cleared by the U.S. Food and Drug Administration (FDA) in intracardiac ultrasound. The algorithm provides automatic left atrial anatomy generation before inserting the catheter into the left atrium. This, according to the company, saves time and provides a highly accurate map.
It also includes the Carto Elevate module. Multipolar with the Optrell mapping catheter allows localized unipolar signals to reduce far field potentials and offer a more accurate activation map. Complex signals identification automatically tracks arrhythmia burden and identifies critical areas of interest when diagnosing the arrhythmia.
Carto Elevate also has pattern acquisition to track arrythmia burden pre- and post-ablation for more informed decision of the relevant premature activation map. An enhanced Confidense module creates optimized maps with higher Smart Index score to ensure maps are continuously improved.
"We are pleased to announce this new version of our CARTO 3 System, which reflects our continued focus on harnessing the latest science and technology to advance tools for electrophysiologists to treat cardiac arrhythmias," said Jasmina Brooks, president, Biosense Webster. "The CARTO 3 System has been the cornerstone of catheter ablation procedures for more than a decade, helping electrophysiologists make treatment decisions. This new version advances the CARTO 3 mapping and ablation experience through enhanced signal analysis, improved substrate characterization, and utilization of ultrasound technology."
The new version of Carto 3 includes Cartsound Fam, an artificial intelligence (AI) cleared by the U.S. Food and Drug Administration (FDA) in intracardiac ultrasound. The algorithm provides automatic left atrial anatomy generation before inserting the catheter into the left atrium. This, according to the company, saves time and provides a highly accurate map.
It also includes the Carto Elevate module. Multipolar with the Optrell mapping catheter allows localized unipolar signals to reduce far field potentials and offer a more accurate activation map. Complex signals identification automatically tracks arrhythmia burden and identifies critical areas of interest when diagnosing the arrhythmia.
Carto Elevate also has pattern acquisition to track arrythmia burden pre- and post-ablation for more informed decision of the relevant premature activation map. An enhanced Confidense module creates optimized maps with higher Smart Index score to ensure maps are continuously improved.
"We are pleased to announce this new version of our CARTO 3 System, which reflects our continued focus on harnessing the latest science and technology to advance tools for electrophysiologists to treat cardiac arrhythmias," said Jasmina Brooks, president, Biosense Webster. "The CARTO 3 System has been the cornerstone of catheter ablation procedures for more than a decade, helping electrophysiologists make treatment decisions. This new version advances the CARTO 3 mapping and ablation experience through enhanced signal analysis, improved substrate characterization, and utilization of ultrasound technology."